APOL1-Associated FSGS: Genetics and Mechanisms
Abstract
These studies aim to help better understand the mechanisms underlying focal segmental glomerulosclerosis (FSGS). FSGS and most forms of kidney disease are much more common in African Americans than other groups. Our group’s published work has shown that this big difference in FSGS and kidney disease rates is largely a result of specific differences in the APOL1 gene that are common in people of recent African ancestry. This disparity in rates of FSGS and chronic kidney disease (CKD) is of major public health importance, as kidney disease is the cause of significant premature death and illness, as well as a major expense. The goal of the studies here is to translate recent advances we have made in understanding how changes in the APOL1 gene affect the function of the APOL1 protein in cells. We will test the effect of altering several different biological pathways in a transgenic mouse model of APOL1-associated FSGS that we have developed. This work aims to improve treatment for APOL1-associated FSGS. FSGS is a Fiscal Year 2019 Peer Reviewed Medical Research Program Topic Area. These studies are expected to give us insight into the best treatment approaches to APOL1-associated FSGS, the form of FSGS that is common in African Americans and others of recent African ancestry. This work may lead to the development of new clinical trials in humans with FSGS and ultimately new and better ways to treat and prevent kidney disease, particularly FSGS.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Mar 10, 2021
- Source ID
- W81XWH2010826
Entities
People
- Martin R. Pollak
Organizations
- Beth Israel Deaconess Medical Center
- United States Army